Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | AGXT | P21549 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893200 | 0.87 | HRH4 (0.45) | TSHRHRH4HRH3TP53L3MBTL1 | |
| SCHEMBL24105171 | 0.81 | TSHR (0.50) | TSHRHRH4HRH3IDO1AGXT | |
| SCHEMBL5440060 | 0.77 | TSHR (0.46) | TSHRHRH4HRH3IDO1AGXT | |
| SCHEMBL4903117 | 0.77 | TSHR (0.46) | TSHRHRH4HRH3IDO1AGXT | |
| SCHEMBL11961679 | 0.73 | TAAR1 (0.41) | HRH3TP53RAB9ANPC1 | |
| SCHEMBL338572 | 0.71 | — | — | |
| Propane SCHEMBL11584021 | 0.71 | TSHR (0.83) | TSHRIDO1TP53AGXTCA1 | |
| SCHEMBL4270861 | 0.71 | P2RX7 (0.32) | — | |
| SCHEMBL4883243 | 0.70 | TSHR (0.44) | TSHRTP53CA1CA2CA7 | |
| Bromide SCHEMBL3127439 | 0.69 | DDAH1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | PFIZER INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1838679-A1 | IMIDAZOLE DERIVATIVES AS ENZYME REVERSE TRANSCRIPTASE MODULATORS | Pfizer Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006072833-A1 | IMIDAZOLE DERIVATIVES AS ENZYME REVERSE TRANSCRIPTASE MODULATORS | PFIZER LIMITED (GB) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | SPR, TPMT, IMPDH1 | TSHR 3874/4885HRH4 530/4885HRH3 621/4885 |
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | POLRMT, POLR1G, POLR2A | TSHR 1981/4885HRH4 1048/4885HRH3 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.